Phase 1 Lung cancer trials recruiting now

All Lung cancer trials, every phase

Other phases for Lung cancer

Phase 1 Lung cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A 2-part Phase 1/2 Open-label Trial on ODM-212
  NCT07563738 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  NCT07227597 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
  NCT05366478 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
  NCT07286149 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
  NCT06839105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
  NCT06892548 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 91 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 76 locations
• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
  NCT06043466 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
  NCT06768151 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
  NCT07367529 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 38 locations
• A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
  NCT06581419 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
  NCT07111520 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 85 locations
• A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
  NCT07231068 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
  NCT07439094 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
  NCT07488923 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
  NCT07354711 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
  NCT05753722 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
  NCT06232083 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
  NCT07632235 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
  NCT06905197 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
  NCT07619599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
  NCT07107490 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
  NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
  NCT06592638 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
  NCT07458347 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
  NCT05948865 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
  NCT07462377 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
  NCT07578571 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
  NCT06789172 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  NCT06956690 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  NCT06427941 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
  NCT07491497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
  NCT05394831 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
  NCT06616766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
  NCT05150691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 204 locations
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 107 locations
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
  NCT07292168 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
  NCT06508307 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
  NCT07416695 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
  NCT07391670 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• A Phase I Study of CFT8919 in Patients With Advanced NSCLC
  NCT06641609 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
  NCT06936735 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
  NCT06792552 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
  NCT07117214 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 2 locations
• A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
  NCT06307925 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
  NCT06380816 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
  NCT07381829 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib Study of GC101 in NSCLC
  NCT06473961 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
  NCT06946927 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
  NCT06306456 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
  NCT05543330 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
  NCT05910827 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
  NCT07361237 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
  NCT07362940 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
  NCT06996782 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 103 locations
• A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
  NCT04550104 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
  NCT02889666 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
  NCT06228326 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants
  NCT07180862 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
  NCT05865002 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
  NCT05789082 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 71 locations
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  NCT07217171 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
  NCT06586957 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 38 locations
• A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
  NCT07623356 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
  NCT07287995 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
  NCT07227025 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Armored CAR T Cells in People With Cancer
  NCT07783477 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
  NCT06706076 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
  NCT05194982 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 8 locations
• A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
  NCT06114511 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
  NCT07056556 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
  NCT06505824 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
  NCT07232420 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
  NCT06764771 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
  NCT07250386 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
  NCT06873555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of DEG6498 in Participants With Solid Tumors
  NCT07244835 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of DM005 in Patients With Advanced Solid Tumors
  NCT06515990 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of DXC014 in Patients With Advanced Solid Tumors.
  NCT07177937 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  NCT06983743 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 24 locations
• A Study of FZ-AD005 in Patients With Advanced Solid Tumors
  NCT06424665 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations

Showing 100 of 515 recruiting trials.

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.